Translational Research in Oncolytic Measles Virotherapy: Early Discoveries And Future Steps

Bibliography

• Hendrix RW , LawrenceJG, HatfullGF, CasjensS: The origins and ongoing evolution of viruses.Trends Microbiol.8 , 504–508 (2000).
   PubMed Web of Science ®Google Scholar
• Bazin H : The Eradication of Smallpox : Edward Jenner and the First and Only Eradication of a Human Infectious Disease.Academic Press, CA, USA (2000).
   Google Scholar
• Liu TC , GalanisE, KirnD: Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.Nat. Clin. Pract. Oncol.4(2) , 101–117 (2007).
   PubMedGoogle Scholar
• Hernandez SA : Observacion de un caso de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares, post-sarampion.Arch. Cubanos Cancer8 , 26–31 (1949).
   Google Scholar
• Tatsuo H , OnoN, TanakaK, YanagiY: SLAM (CDw150) is a cellular receptor for measles virus.Nature406(6798) , 893–897 (2000).
   PubMed Web of Science ®Google Scholar
• Griffin DE , PanCH: Measles: old vaccines, new vaccines.Curr. Top. Microbiol. Immunol.330 , 191–212 (2009).
   PubMed Web of Science ®Google Scholar
• Dorig RE , MarcilA, ChopraA, RichardsonCD: The human CD46 molecule is a receptor for measles virus (Edmonston strain).Cell75(2) , 295–305 (1993).
   PubMed Web of Science ®Google Scholar
• Anderson BD , NakamuraT, RussellSJ, PengKW: High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.Cancer Res.64(14) , 4919–4926 (2004).
   PubMed Web of Science ®Google Scholar
• Fishelson Z , DoninN, ZellS, SchultzS, KirschfinkM: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.Mol. Immunol.40(2–4) , 109–123 (2003).
   PubMed Web of Science ®Google Scholar
• Blechacz B , RussellSJ: Measles virus as an oncolytic vector platform.Curr. Gene Ther.8(3) , 162–175 (2008).
   PubMed Web of Science ®Google Scholar
• Russell SJ , PengKW: Measles virus for cancer therapy.Curr. Top. Microbiol. Immunol.330 , 213–241 (2009).
   PubMed Web of Science ®Google Scholar
• Phuong LK , AllenC, PengKWet al. : Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.Cancer Res.63(10) , 2462–2469 (2003).
   PubMed Web of Science ®Google Scholar
• Radecke F , SpielhoferP, SchneiderHet al. : Rescue of measles viruses from cloned DNA.EMBO J.14(23) , 5773–5784 (1995).
   PubMed Web of Science ®Google Scholar
• Nakamura T , PengKW, HarveyMet al. : Rescue and propagation of fully retargeted oncolytic measles viruses.Nat. Biotechnol.23(2) , 209–214 (2005).
   PubMed Web of Science ®Google Scholar
• Springfeld C , vonMessling V, FrenzkeM, UngerechtsG, BuchholzCJ, CattaneoR: Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.Cancer Res.66(15) , 7694–7700 (2006).
   PubMed Web of Science ®Google Scholar
• Billeter MA , NaimHY, UdemSA: Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses.Curr. Top. Microbiol. Immunol.329 , 129–162 (2009).
   PubMed Web of Science ®Google Scholar
• Hadac EM , PengKW, NakamuraT, RussellSJ: Reengineering paramyxovirus tropism.Virology329(2) , 217–225 (2004).
   PubMed Web of Science ®Google Scholar
• Heinzerling L , KunziV, OberholzerPA, KundigT, NaimH, DummerR: Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells.Blood106(7) , 2287–2294 (2005).
   PubMed Web of Science ®Google Scholar
• Peng KW , TenEyckCJ, GalanisE, KalliKR, HartmannLC, RussellSJ: Intraperitoneal therapy of ovarian cancer using an engineered measles virus.Cancer Res.62(16) , 4656–4662 (2002).
   PubMed Web of Science ®Google Scholar
• Dingli D , PengKW, HarveyMEet al. : Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.Blood103(5) , 1641–1646 (2004).
   PubMed Web of Science ®Google Scholar
• Dingli D , PengKW, HarveyMEet al. : Interaction of measles virus vectors with Auger electron emitting radioisotopes.Biochem. Biophys. Res. Commun.337(1) , 22–29 (2005).
   PubMed Web of Science ®Google Scholar
• Fulci G , BreymannL, GianniDet al. : Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.Proc. Natl Acad. Sci. USA103(34) , 12873–12878 (2006).
   PubMed Web of Science ®Google Scholar
• Hasegawa K , PhamL, O‘ConnorMK, FederspielMJ, RussellSJ, PengKW: Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.Clin. Cancer Res.12(6) , 1868–1875 (2006).
   PubMed Web of Science ®Google Scholar
• Kambara H , SaekiY, ChioccaEA: Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.Cancer Res.65(24) , 11255–11258 (2005).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL , KloosRT: Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer.J. Clin. Endocrinol. Metab.86(4) , 1447–1463 (2001).
   PubMed Web of Science ®Google Scholar
• Ong HT , HasegawaK, DietzAB, RussellSJ, PengKW: Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.Gene Ther.14(4) , 324–333 (2007).
   PubMed Web of Science ®Google Scholar
• Msaouel P , DispenzieriA, GalanisE: Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Curr. Opin. Mol. Ther.11(1) , 43–53 (2009).
   PubMed Web of Science ®Google Scholar
• Myers RM , GreinerSM, HarveyMEet al. : Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.Clin. Pharmacol. Ther.82(6) , 700–710 (2007).
   PubMed Web of Science ®Google Scholar
• Myers R , HarveyM, KaufmannTJet al. : Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.Hum. Gene Ther.19(7) , 690–698 (2008).
   PubMed Web of Science ®Google Scholar
• Galanis E , HartmannLC, ClibyWAet al. : Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.Cancer Res.70(3) , 875–882 (2010).
   PubMed Web of Science ®Google Scholar
• Prestwich RJ , ErringtonF, DiazRMet al. : The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Hum. Gene Ther.20(10) , 1119–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Iankov ID , BlechaczB, LiuCet al. : Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.Mol. Ther.15(1) , 114–122 (2007).
   PubMed Web of Science ®Google Scholar
• Mader EK , MaeyamaY, LinYet al. : Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.Clin. Cancer Res.15(23) , 7246–7255 (2009).
   PubMed Web of Science ®Google Scholar
• Ungerechts G , SpringfeldC, FrenzkeMEet al. : An immunocompetent murine model for oncolysis with an armed and targeted measles virus.Mol. Ther.15(11) , 1991–1997 (2007).
   PubMed Web of Science ®Google Scholar
• Haralambieva I , IankovI, HasegawaK, HarveyM, RussellSJ, PengKW: Engineering oncolytic measles virus to circumvent the intracellular innate immune response.Mol. Ther.15(3) , 588–597 (2007).
   PubMed Web of Science ®Google Scholar
• Li H , PengKW, DingliD, KratzkeRA, RussellSJ: Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.Cancer Gene Ther.17(8) , 550–558 (2010).
   PubMed Web of Science ®Google Scholar